Genetic Non Current Liabilities Total vs Total Cash From Operating Activities Analysis
GTG Stock | 0.04 0.00 0.00% |
Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Non Current Liabilities Total and its Total Cash From Operating Activities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Non Current Liabilities Total vs Total Cash From Operating Activities
Non Current Liabilities Total vs Total Cash From Operating Activities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Non Current Liabilities Total account and Total Cash From Operating Activities. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Genetic Technologies' Non Current Liabilities Total and Total Cash From Operating Activities is -0.04. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Cash From Operating Activities in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Non Current Liabilities Total and Total Cash From Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Genetic Technologies are associated (or correlated) with its Total Cash From Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Cash From Operating Activities has no effect on the direction of Non Current Liabilities Total i.e., Genetic Technologies' Non Current Liabilities Total and Total Cash From Operating Activities go up and down completely randomly.
Correlation Coefficient | -0.04 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Current Liabilities Total
Total Cash From Operating Activities
Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Genetic Technologies' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is expected to grow at the current pace this year, whereas Issuance Of Capital Stock is likely to drop slightly above 2.2 M in 2025.
2022 | 2023 | 2024 | 2025 (projected) | Total Operating Expenses | 18.1M | 3.9M | 3.5M | 3.3M | Cost Of Revenue | 4.3M | 3.8M | 3.4M | 1.8M |
Genetic Technologies fundamental ratios Correlations
Click cells to compare fundamentals
Genetic Technologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Genetic Technologies fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 23.0M | 20.8M | 14.9M | 6.2M | 5.6M | 5.3M | |
Other Current Liab | 955.5K | 1.6M | 1.3M | 1.1M | 1.0M | 901.4K | |
Total Current Liabilities | 1.4M | 3.8M | 3.3M | 4.2M | 3.8M | 2.0M | |
Total Stockholder Equity | 21.5M | 16.4M | 11.2M | 1.8M | 1.6M | 1.6M | |
Property Plant And Equipment Net | 637.7K | 953.3K | 599.2K | 264.5K | 238.0K | 226.1K | |
Net Debt | (20.7M) | (11.1M) | (7.3M) | (145.4K) | (130.9K) | (137.4K) | |
Retained Earnings | (143.1M) | (150.2M) | (156.7M) | (166.4M) | (149.7M) | (142.3M) | |
Accounts Payable | 269.7K | 1.2M | 838.0K | 1.5M | 1.3M | 789.6K | |
Cash | 20.9M | 11.7M | 7.9M | 1.0M | 1.2M | 1.1M | |
Non Current Assets Total | 735.6K | 6.1M | 4.2M | 2.5M | 2.2M | 2.1M | |
Non Currrent Assets Other | (9.5M) | (6.1M) | (4.2M) | 81.7K | 73.5K | 77.2K | |
Cash And Short Term Investments | 20.9M | 11.7M | 7.9M | 1.0M | 1.2M | 1.1M | |
Net Receivables | 1.1M | 2.4M | 191.9K | 2.1M | 2.4M | 2.6M | |
Common Stock Shares Outstanding | 85.4M | 92.2M | 101.4M | 132.2M | 119.0M | 113.0M | |
Liabilities And Stockholders Equity | 23.0M | 20.8M | 14.9M | 6.2M | 5.6M | 5.3M | |
Inventory | 76.9K | 398.2K | 325.9K | 206.5K | 185.8K | 176.5K | |
Other Stockholder Equity | 1.2M | (10.5M) | (4.9M) | (4.6M) | (4.2M) | (4.0M) | |
Total Liab | 1.4M | 4.4M | 3.7M | 4.4M | 3.9M | 2.3M | |
Property Plant And Equipment Gross | 1.3M | 1.9M | 1.8M | 1.5M | 1.4M | 946.1K | |
Total Current Assets | 22.2M | 14.7M | 10.5M | 3.7M | 4.2M | 4.0M | |
Common Stock | 153.6M | 155.1M | 161.3M | 163.8M | 188.4M | 99.3M | |
Property Plant Equipment | 440.2K | 637.7K | 953.3K | 599.2K | 539.3K | 876.6K | |
Short Long Term Debt Total | 204.0K | 652.5K | 532.9K | 875.2K | 787.7K | 509.7K | |
Other Current Assets | 182.6K | 18.2K | 2.1M | 341.7K | 393.0K | 461.4K | |
Short Term Debt | 179.6K | 264.1K | 303.6K | 852.3K | 980.1K | 1.0M | |
Short Term Investments | 1.9K | 13.3K | 17.4K | 18.8K | 16.9K | 16.1K | |
Non Current Liabilities Total | 33.3K | 558.9K | 381.6K | 160.6K | 144.6K | 137.4K | |
Accumulated Other Comprehensive Income | 11.0M | 11.5M | 6.5M | 4.4M | 5.0M | 4.3M | |
Current Deferred Revenue | 635.0 | 814.2K | 849.2K | 741.6K | 852.9K | 895.5K | |
Other Liab | 979.2K | 8.9K | 170.5K | 152.3K | 175.2K | 133.1K | |
Net Tangible Assets | 13.0M | 21.5M | 11.3M | 7.5M | 8.7M | 11.1M | |
Long Term Debt Total | 240.9K | 24.4K | 388.4K | 229.3K | 263.7K | 138.8K | |
Net Invested Capital | 21.5M | 16.4M | 11.2M | 2.5M | 2.8M | 2.7M | |
Net Working Capital | 20.8M | 10.9M | 7.2M | (500.1K) | (450.1K) | (427.6K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.